Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years

• Main Authors: Andreas Wollenberg (Author), Masanori Ikeda (Author), Chia-Yu Chu (Author), Lawrence F. Eichenfield (Author), Marieke M. B. Seyger (Author), Apurva Prakash (Author), Robinette Angle (Author), Danting Zhu (Author), Marco Pontes (Author), Amy S. Paller (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background Baricitinib, an oral selective Janus kinase inhibitor, improved clinical signs and symptoms of moderate-to-severe atopic dermatitis (AD) at week 16 in the phase 3 pediatric study BREEZE-AD-PEDS.Objective To assess longer-term efficacy and safety of baricitinib in pediatric patients aged 2...